On May 27, 2022 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, reported new interim data from Part A of the Phase II TACTI-002 trial in 1st line NSCLC has been published today in an abstract at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s (ASCO) (Free ASCO Whitepaper) 2022 Annual Meeting (Press release, Immutep, MAY 27, 2022, View Source [SID1234615248]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data from the trial will be presented in an Oral Presentation on 3 June 2022. Importantly, while the abstract contains data from the first 75 patients with a data cut off of January 2022, the Oral Presentation will present data from all 114 patients with a more recent data cut off and will be the subject of a further announcement from the Company.

Immutep also announces the publication of an abstract for the design of the ongoing Phase IIb TACTI-003 trial that will be presented as a Trial-in-Progress Poster Presentation at ASCO (Free ASCO Whitepaper) 2022.

The respective abstracts are available via the links below and www.immutep.com. Similarly, the presentations will be available at the times indicated below on ASCO (Free ASCO Whitepaper).org and subsequently made available on Immutep’s website.

TACTI-002 Abstract
Title: A Phase II study (TACTI-002) in 1st line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: updated results from a PD-L1 unselected population
Abstract link: View Source 2022/ASCO 2022_TACTI-002 part A_Abstract_Final.pdf
Oral presentation date: Friday 3 June 2022 at 1:00pm, US Central Daylight Time (CDT)

TACTI-003 Abstract
Title: TACTI-003: A randomized Phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous-cell carcinoma
Abstract link: View Source 2022/ASCO 2022_TACTI-003_TIP_Abstract_Final.pdf
Poster date: Monday 6 June 2022 at 1:15pm US CDT

On May 27, 2022 NEX-I reported that the company selected NXI-101, a new antibody treatment for non-small cell lung cancer that targets immunotherapy-refractory factors (Press release, NEX-I, MAY 27, 2022, View Source;mode=VIEW&num=15&category=&findType=&findWord=&sort1=&sort2=&page=3 [SID1234643432]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO Kyung-wan Yoon"NXI-101Not only does it improve the survival rate of patients who do not respond to existing immunotherapy treatments,,As an anticancer drug that guarantees the patient’s quality of life after treatment, it will bring a new paradigm to the cancer immunotherapy market."said.

The national new drug development project is a domestic pharmaceutical·To strengthen the global competitiveness of the bio industry and secure pharmaceutical sovereignty, which is an essential condition for public health, pharmaceutical companies and academia·kite·Based on bottle open innovation strategy,A pan-ministerial country that supports all stages of new drug developmentR&DStarting this year as a business10years2article2000Investing billions of won.

With the selection of this project, NexI plans to2yearsNXI-101You will receive support for the research costs necessary to derive the lead material.. NXI-101It targets immune evasion factors specifically secreted by cancer cells.First-in-classIt is a new antibody drug..Immune evasion factors are the cause of refractoriness to anticancer immunotherapy.,Controlling this can significantly improve the efficacy of anticancer immunotherapy..

The company said"New drugs under development are derived based on data from a number of immunotherapy-refractory animal models established in-house and from patients who are actually refractory to anti-cancer immunotherapy, so effective clinical efficacy can be expected."He said.

Meanwhile,Nexi this year4It is a new bio venture company established in February..Chief Scientific Officer of Genome & Company(CSO)·CEO Kyung-wan Yoon, who served as vice president,20Through more than a year of research on incurable cancer diseases, many anticancer drugs have been developed.·Professor Kim Tae-woo of Korea University College of Medicine, who has research achievements in immunotherapy, is the Chief Technology Officer.(CTO)I am in charge of.

On May 27, 2022 Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, reported that it will be presenting a poster at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held at McCormick Place in Chicago and virtually from June 3-7, 2022 (Press release, Bolt Biotherapeutics, MAY 27, 2022, View Source [SID1234618688]). The poster is titled "Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates (ISACs)."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data being presented at ASCO (Free ASCO Whitepaper) demonstrate that myeloid cells are consistently present in solid tumors. We believe this represents an attractive cellular target to address cancer more broadly. Myeloid cells are key cell types that serve as immunologic sentinels within the tumor microenvironment and can directly kill tumor cells or activate long-lasting cytotoxic T cells," said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. "Myeloid-targeted therapies, as single-agents or in combination with approved therapies, have the potential to benefit patients who may or may not have previously benefited from T cell-targeted approaches."

Bolt Biotherapeutics is currently developing a pipeline of myeloid-targeting therapies, including immune-stimulating antibody conjugates (ISACs) and BDC-3042 (a Dectin-2 agonistic antibody), designed to kill tumors through activation of myeloid cells and subsequent recruitment of T cells. Bolt researchers characterized the myeloid immune landscape of tumor microenvironments from five solid tumor types. The data demonstrate that myeloid cells are present in all tested tumor microenvironments, including those with low T cell infiltration. These findings support the potential for myeloid-directed therapies to activate the innate immune system as a bridge to adaptive immunity, including patient populations who have demonstrated resistance to T cell-mediated immune checkpoint blockade. The data also validate the tumor cell expression of tumor antigens HER2, CEA, and PD-L1, all of which are targets of Boltbody ISAC candidates.

The ASCO (Free ASCO Whitepaper) abstract and poster presentation can be found on the Bolt website under Events & Presentations. Details regarding the presentation are as follows.

Title: Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune stimulating antibody conjugates (ISACs)
Presented by: Jason Ptacek, Ph.D.
Poster Session: Developmental Therapeutics – Immunotherapy
Time: Sunday, June 5, 8:00 a.m. – 11:00 a.m. CDT
Abstract Number: 2557
Poster Number: 212

On May 27, 2022 Gnubiotics Sciences, a biotech company pioneering immunomodulatory glycopeptides, reported that results from its GLAAD technology program in Colorectal Cancer (CRC) will be presented in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, scheduled for June 3-7, 2022 in Chicago, Illinois (USA) (Press release, Gnubiotics Sciences, MAY 27, 2022, View Source [SID1234615171]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster entitled Exploiting GLAAD molecules to drive an antitumor immune response in a colorectal cancer mouse model will be presented by Yemi Adesokan, Ph.D., Gnubiotics’s Chief Executive Officer, on June 5.

"We are thrilled to present compelling pre-clinical efficacy data in colorectal cancer. These findings nicely complement previous work in melanoma presented earlier this year at AACR (Free AACR Whitepaper). Our Glycopeptides with tumor-associated Antigen and Adjuvant Delivery (GLAAD) technology is designed to drive and boost immune responses directed against various solid tumors and we are excited that the technology continues to deliver promising preclinical data, paving the way for future clinical development. With our collaborators at the University of Zurich we demonstrated that our proprietary glycopeptide candidates were capable to control tumor growth either alone or in combination with existing treatment. We are convinced that glycan-based strategies like our GLAAD approach bear great potential for safe and effective immunotherapies and respond to the urgent need for new modalities for non-responding patients that are otherwise left with few alternative treatments," stated Yemi Adesokan, Ph.D., Gnubiotics’s Chief Executive Officer.

Abstract Title: Exploiting GLAAD molecules to drive an antitumor immune response in a colorectal cancer mouse model.

Abstract Number: 2565

Session Title: Developmental Therapeutics—Immunotherapy

Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT

The Poster will also be made available for browsing on the first day of the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting. Viewers will have the possibility to e-mail questions and comments to the presenter.

On May 27, 2022 Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), reported that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will participate in two upcoming investor conferences in June (Press release, Ambrx, MAY 27, 2022, View Source [SID1234615208]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen’s 3rd Annual Oncology Innovation Summit. Dr. Tian will participate in an analyst led fireside chat on Thursday, June 2 at 11:30 AM Pacific Time / 2:30 PM Eastern Time.

JMP Securities Life Sciences Conference. Dr. Tian will present on Thursday, June 16 at 11:00 AM Pacific Time / 2:00 PM Eastern Time.

Interested parties can access the live and pre-recorded webcasts for these conferences from the Investor Relations section of the company’s website at www.Ambrx.com. The webcast replays will be available after the conclusion of the respective presentations for approximately 90 days.